as 06-28-2024 4:00pm EST
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Founded: | N/A | Country: | United States |
Employees: | N/A | City: | NORTH CHICAGO |
Market Cap: | 277.3B | IPO Year: | N/A |
Target Price: | $185.00 | AVG Volume (30 days): | 6.5M |
Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
Dividend Yield: | 3.62% | Dividend Payout Frequency: | Quarterly |
EPS: | 3.37 | EPS Growth: | -20.52 |
52 Week Low/High: | $132.70 - $182.89 | Next Earning Date: | 07-25-2024 |
Revenue: | $54,403,000,000 | Revenue Growth: | -4.12% |
Revenue Growth (this year): | 3.67% | Revenue Growth (next year): | 5.69% |
Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Donoghoe Nicholas | ABBV | EVP, CHIEF BUS/STRAT OFFICER | Mar 20 '24 | Sell | $176.30 | 21,082 | $3,716,756.60 | 55,903 | SEC Form 4 |
Stewart Jeffrey Ryan | ABBV | EVP, CHIEF COMMERCIAL OFFICER | Mar 18 '24 | Sell | $178.85 | 26,110 | $4,669,773.50 | 93,780 | SEC Form 4 |
Stewart Jeffrey Ryan | ABBV | EVP, CHIEF COMMERCIAL OFFICER | Mar 18 '24 | Sell | $179.03 | 5,099 | $912,873.97 | 88,681 | SEC Form 4 |
Stewart Jeffrey Ryan | ABBV | EVP, CHIEF COMMERCIAL OFFICER | Mar 18 '24 | Sell | $178.69 | 27,740 | $4,956,860.60 | 60,941 | SEC Form 4 |
RICHMOND TIMOTHY J. | ABBV | EVP, CHIEF HR OFFICER | Mar 1 '24 | Sell | $176.40 | 15,412 | $2,718,676.80 | 74,105 | SEC Form 4 |
RICHMOND TIMOTHY J. | ABBV | EVP, CHIEF HR OFFICER | Mar 1 '24 | Sell | $177.71 | 30,288 | $5,382,480.48 | 43,817 | SEC Form 4 |
RICHMOND TIMOTHY J. | ABBV | EVP, CHIEF HR OFFICER | Mar 1 '24 | Sell | $176.35 | 9,853 | $1,737,576.55 | 33,964 | SEC Form 4 |
RICHMOND TIMOTHY J. | ABBV | EVP, CHIEF HR OFFICER | Mar 1 '24 | Sell | $177.71 | 20,127 | $3,576,769.17 | 13,837 | SEC Form 4 |
Michael Robert A. | ABBV | PRES & CHIEF OPERATING OFFICER | Feb 28 '24 | Sell | $176.44 | 21,560 | $3,804,046.40 | 145,964 | SEC Form 4 |
Michael Robert A. | ABBV | PRES & CHIEF OPERATING OFFICER | Feb 28 '24 | Sell | $176.46 | 47,319 | $8,349,910.74 | 98,645 | SEC Form 4 |
Siatis Perry C | ABBV | EVP, GC AND SECRETARY | Feb 28 '24 | Sell | $177.05 | 6,504 | $1,151,533.20 | 13,784 | SEC Form 4 |
Siatis Perry C | ABBV | EVP, GC AND SECRETARY | Feb 28 '24 | Sell | $178.04 | 3,387 | $603,021.48 | 10,397 | SEC Form 4 |
GONZALEZ RICHARD A | ABBV | CHAIRMAN OF THE BOARD AND CEO | Feb 28 '24 | Sell | $177.27 | 138,616 | $24,572,458.32 | 519,099 | SEC Form 4 |
Buckbee Kevin K | ABBV | SVP, CONTROLLER | Feb 28 '24 | Sell | $176.65 | 5,144 | $908,687.60 | 6,983 | SEC Form 4 |
Reents Scott T | ABBV | EVP, CHIEF FINANCIAL OFFICER | Feb 23 '24 | Sell | $177.44 | 14,140 | $2,509,001.60 | 27,065 | SEC Form 4 |
Siatis Perry C | ABBV | EVP, GC AND SECRETARY | Feb 23 '24 | Sell | $177.51 | 13,753 | $2,441,295.03 | 28,173 | SEC Form 4 |
SALEKI-GERHARDT AZITA | ABBV | EVP, CHIEF OPERATIONS OFFICER | Feb 21 '24 | Sell | $173.71 | 52,870 | $9,184,047.70 | 243,944 | SEC Form 4 |
Donoghoe Nicholas | ABBV | EVP, CHIEF BUS/STRAT OFFICER | Dec 26 '23 | Sell | $154.72 | 2,912 | $450,544.64 | 55,903 | SEC Form 4 |
ABBV Breaking Stock News: Dive into ABBV Ticker-Specific Updates for Smart Investing
Yahoo Finance Video
2 days ago
Pharmaceutical Technology
2 days ago
Simply Wall St.
2 days ago
Zacks
2 days ago
Zacks
2 days ago
Zacks
2 days ago
Pharmaceutical Technology
2 days ago
MT Newswires
2 days ago
The information presented on this page, "ABBV AbbVie Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.